The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings.

Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price ...

A recent Japanese study confirms that switching from originator infliximab to biosimilars maintains remission in patients who ...

A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options.

HLX02 shows promise as a safe, effective trastuzumab biosimilar for HER2-positive metastatic breast cancer, enhancing treatment access and affordability. Doctors in China are seeing encouraging ...

Number 5: A 10-year prospective follow-up of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim biosimilar, reinforcing its long-term safety for donor mobilization.

Another ranibizumab biosimilar, Byooviz, is approved, but Coherus’ product is the first deemed interchangeable, which involves additional FDA requirements that allow substitution without intervention ...